Trial Outcomes & Findings for Digital Therapeutic for Chronic Pain Feasibility Study (NCT NCT06000007)
NCT ID: NCT06000007
Last Updated: 2026-03-31
Results Overview
This self-report questionnaire consists of is a six-item that assesses the impact of pain on various aspects of a person's life (e.g., social, cognitive, emotional, physical and recreational activities) over the last 7 days. Responses are scored using a 5-point ordinal rating scale from 1 to 5 (1=Not at all, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Very much). Raw score totals are converted to T-score using the scoring manual. T-score of 50 is the mean for the U.S. general population with a standard deviation of 10; the higher the T-score, the worse the pain interference.
COMPLETED
PHASE2
108 participants
will be measured at baseline, 1-month, 3-month, and 6 month intervals
2026-03-31
Participant Flow
Eligibility: aged \>=18, pain experience current and present for \>=3 months, \>=1 ICD code for common pain related condition, \>=2 primary care visits within last 12 months at time of recruitment, PROMIS Pain Interference Short Form 6b T-score \>=55, daily smartphone access, ability to download an app, willingness to engage in a 3-month chronic pain self-management program administered via an app, speak English, and consented. Exclusions: cancer pain surgery within 3 months, pregnant, on hospice.
Patients were invited to participate via direct email with a link to an interest survey with three options: eligibility survey vs request a call back vs opt out. Those eligible were directed to an e-consent form requiring confirmation vs request a call vs confirm that they no interest in participation. Patients who confirmed interest were asked to e-consent. A study coordinator counter-signed the e-consent form and follow up with any call requests, and if needed assist with consent by phone.
Participant milestones
| Measure |
Treatment as Usual
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
|
Intervention Arm
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
|
|---|---|---|
|
Overall Study
STARTED
|
43
|
49
|
|
Overall Study
COMPLETED
|
40
|
38
|
|
Overall Study
NOT COMPLETED
|
3
|
11
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Digital Therapeutic for Chronic Pain Feasibility Study
Baseline characteristics by cohort
| Measure |
Treatment as Usual
n=43 Participants
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
|
Intervention Arm
n=49 Participants
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
|
Total
n=92 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=4 Participants
|
0 Participants
n=28 Participants
|
0 Participants
n=10 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
34 Participants
n=4 Participants
|
38 Participants
n=28 Participants
|
72 Participants
n=10 Participants
|
|
Age, Categorical
>=65 years
|
9 Participants
n=4 Participants
|
11 Participants
n=28 Participants
|
20 Participants
n=10 Participants
|
|
Sex/Gender, Customized
Gender
|
0 Participants
n=4 Participants
|
0 Participants
n=28 Participants
|
0 Participants
n=10 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=4 Participants
|
0 Participants
n=28 Participants
|
0 Participants
n=10 Participants
|
|
Race (NIH/OMB)
Asian
|
4 Participants
n=4 Participants
|
7 Participants
n=28 Participants
|
11 Participants
n=10 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=4 Participants
|
2 Participants
n=28 Participants
|
2 Participants
n=10 Participants
|
|
Race (NIH/OMB)
Black or African American
|
6 Participants
n=4 Participants
|
7 Participants
n=28 Participants
|
13 Participants
n=10 Participants
|
|
Race (NIH/OMB)
White
|
22 Participants
n=4 Participants
|
21 Participants
n=28 Participants
|
43 Participants
n=10 Participants
|
|
Race (NIH/OMB)
More than one race
|
9 Participants
n=4 Participants
|
8 Participants
n=28 Participants
|
17 Participants
n=10 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=4 Participants
|
4 Participants
n=28 Participants
|
6 Participants
n=10 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
10 Participants
n=4 Participants
|
9 Participants
n=28 Participants
|
19 Participants
n=10 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
32 Participants
n=4 Participants
|
40 Participants
n=28 Participants
|
72 Participants
n=10 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=4 Participants
|
0 Participants
n=28 Participants
|
1 Participants
n=10 Participants
|
PRIMARY outcome
Timeframe: will be measured at baseline, 1-month, 3-month, and 6 month intervalsPopulation: The difference in sample size between the Participant Flow section and this section is due to incomplete surveys, which were excluded from the analysis.
This self-report questionnaire consists of is a six-item that assesses the impact of pain on various aspects of a person's life (e.g., social, cognitive, emotional, physical and recreational activities) over the last 7 days. Responses are scored using a 5-point ordinal rating scale from 1 to 5 (1=Not at all, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Very much). Raw score totals are converted to T-score using the scoring manual. T-score of 50 is the mean for the U.S. general population with a standard deviation of 10; the higher the T-score, the worse the pain interference.
Outcome measures
| Measure |
Treatment as Usual
n=38 Participants
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
|
Intervention Arm
n=46 Participants
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
|
|---|---|---|
|
PROMIS Pain Interference Scale - Short Form 6b
baseline difference scores
|
62.1 T-score - difference scores between arms
Standard Deviation 5.5
|
62.1 T-score - difference scores between arms
Standard Deviation 4.2
|
|
PROMIS Pain Interference Scale - Short Form 6b
1-month different scores
|
62.8 T-score - difference scores between arms
Standard Deviation 5.7
|
60.8 T-score - difference scores between arms
Standard Deviation 5.6
|
|
PROMIS Pain Interference Scale - Short Form 6b
3-month difference
|
61.9 T-score - difference scores between arms
Standard Deviation 6.2
|
61.2 T-score - difference scores between arms
Standard Deviation 5.6
|
|
PROMIS Pain Interference Scale - Short Form 6b
6-month difference
|
61.0 T-score - difference scores between arms
Standard Deviation 6.1
|
59.9 T-score - difference scores between arms
Standard Deviation 5.7
|
SECONDARY outcome
Timeframe: will be measured at baseline, 1-month, 3-month, and 6 month intervalsPopulation: The difference in sample size between the Participant Flow section and this section is due to incomplete surveys, which were excluded from the analysis.
This self-report questionnaire consists of 9 items assessing depressive symptoms consistent with criteria for Major Depressive Disorder over the past two weeks. Each item is rated on a 4-point Likert scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day). Item scores are summed to produce a total score ranging from 0 to 27, with higher scores indicating greater severity of depressive symptoms (worse outcome). A typical cut-off score for probable depression is ≥ 10 points. The measure has demonstrated strong psychometric properties, including high levels of sensitivity and specificity for identifying major depressive disorder.
Outcome measures
| Measure |
Treatment as Usual
n=40 Participants
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
|
Intervention Arm
n=49 Participants
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
|
|---|---|---|
|
Patient Health Questionnaire 9 (PHQ-9)
baseline difference
|
8.2 units on a scale
Standard Deviation 6.1
|
8.5 units on a scale
Standard Deviation 5.1
|
|
Patient Health Questionnaire 9 (PHQ-9)
1-month difference
|
8.3 units on a scale
Standard Deviation 6.4
|
8.7 units on a scale
Standard Deviation 5.3
|
|
Patient Health Questionnaire 9 (PHQ-9)
3-month difference
|
8.8 units on a scale
Standard Deviation 5.8
|
7.9 units on a scale
Standard Deviation 5.9
|
|
Patient Health Questionnaire 9 (PHQ-9)
6-month difference
|
7.7 units on a scale
Standard Deviation 5.7
|
8.6 units on a scale
Standard Deviation 5.4
|
SECONDARY outcome
Timeframe: will be measured at baseline, 1-month, 3-month, and 6 month intervalsPopulation: The GAD-7 measure was accidentally left off of the baseline measure for some participants at the start of the study, so the total # of GAD-7 baseline participants is lower than the total # for the other outcome measures.
anxiety symptom measure; scores range from 0-21; higher scores are worse
Outcome measures
| Measure |
Treatment as Usual
n=38 Participants
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
|
Intervention Arm
n=48 Participants
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
|
|---|---|---|
|
Generalized Anxiety Disorder 7 (GAD-7)
baseline difference
|
6.6 units on a scale
Standard Deviation 5.6
|
8.2 units on a scale
Standard Deviation 5.3
|
|
Generalized Anxiety Disorder 7 (GAD-7)
1-month difference
|
6.9 units on a scale
Standard Deviation 6.1
|
8.0 units on a scale
Standard Deviation 5.5
|
|
Generalized Anxiety Disorder 7 (GAD-7)
3-month difference
|
6.8 units on a scale
Standard Deviation 5.2
|
7.2 units on a scale
Standard Deviation 5.9
|
|
Generalized Anxiety Disorder 7 (GAD-7)
6-month difference
|
6.3 units on a scale
Standard Deviation 57
|
7.0 units on a scale
Standard Deviation 5.4
|
Adverse Events
Treatment as Usual
Intervention Arm
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place